Accelerating Early Phase Clinical Development in the UK:

Posted:
24
October 2011

The Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI) welcomes you to attend its annual meeting being held on Friday 18th November at the Wellcome Collection Conference Centre, London from 13h30 to 17h30.The Association has been in existence for over nearly 2 decades and has forged links with both other scientific societies with similar interests and with professional bodies such as the ABPI and ICR. The AHPPI's mission is to offer a framework for discussion and to exchange on current topics in applied Human Pharmacology and early phase drug development. Its aim is also to provide training, education and guidance and provide a forum for innovation and the development of new methods and efficiencies.The topic of this meeting will focus on "Accelerating Early Phase Clinical Development in the UK", and as always we expect to have a panel of excellent speakers from such organisations as ABPI, MHRA, NHS, pharmaceutical and CRO industries. For further details for what's in store for the day, please click here to view the full meeting agenda or here to register.Furthermore there will be the opportunity to attend the guided tours of the Wellcome collections and exhibitions. If you are interested in attending a tour on the day of the AHPPI meeting, please contact us for more details.This meeting has been awarded four Continuing Professional Development points by the Faculty of Pharmaceutical Medicine and is open to AHPPI members and non-members. On behalf of the AHPPI we cordially invite you to attend and look forward to seeing you next month!

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more